Evidence map›Paper›PMID 42808164›Full record

ArticleDiabetes & vascular disease research

Benefits of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide-1 receptor agonists in older patients with type 2 diabetes.

Ibrahim Mortada, Krishna Paul, James Rice, Noah Joseph, Trevor L Raum, Mohanad Albayyaa, Diann Gaalema, Dietrich Jehle, Thomas A Blackwell, Hani Jneid

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ibrahim MortadaDepartment of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0009-0006-9215-880X
Krishna PaulDepartment of Emergency Medicine, University of Texas Medical Branch, Galveston, TX, USA.
James RiceDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0009-0002-3473-0880
Noah JosephJohn Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Trevor L RaumJohn Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0009-0006-5547-1282
Mohanad AlbayyaaDepartment of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0003-4185-5294
Diann GaalemaDepartment of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-6463-9925
Dietrich JehleDepartment of Emergency Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0009-0002-6006-3903
Thomas A BlackwellDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0009-0009-0659-2100
Hani JneidDepartment of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0002-8754-358X

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
NCATS NIH HHS UL1 TR001439
6 · The paper itself

Abstract

BackgroundType 2 diabetes mellitus (T2DM) increases the risk of cardiovascular and neurocognitive complications. GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2is) have pleiotropic effects beyond glycemic control, but comparative long-term data on dementia, cardiovascular events, and mortality in older adults are limited.MethodsThis retrospective cohort study used the TriNetX US Collaborative Network. Adults ≥60 years with T2DM on metformin plus either GLP-1 RAs or SGLT2is (n=56,211 per cohort after matching, 2014-2020) were propensity-score matched on demographic and clinical characteristics. Five-year outcomes included incident Alzheimer's disease, vascular dementia, other dementia, dementia-related medication use, NSTEMI, STEMI, and all-cause mortality.ResultsAfter propensity-score matching, GLP-1 RA use was associated with higher risks of Alzheimer's disease (RR 1.33, 95% CI 1.18-1.48), vascular dementia (RR 1.56, 95% CI 1.39-1.76), other dementia (RR 1.33, 95% CI 1.21-1.47), dementia-related medication initiation, and all-cause mortality (RR 1.11, 95% CI 1.08-1.15) compared with SGLT2is. NSTEMI and STEMI risks did not differ significantly between groups.ConclusionsIn older adults with T2DM, SGLT2is were associated with lower risks of dementia, dementia-related medication use, and all-cause mortality compared with GLP-1 RAs in propensity-score matched cohorts. These observational findings are hypothesis-generating and should be confirmed in prospective studies.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsIncretinsSodium-Glucose Transporter 2 InhibitorsAgedAged, 80 and overAge FactorsFemaleGlucagon-Like Peptide-1 ReceptorHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIncretinsSodium-Glucose Transporter 2 InhibitorsCardiologyDementiaDiabetes mellitus type 2Glucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitors

Identifiers

PMID42808164
PMCPMC13735463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.